VTGN News and Press, VistaGen Therapeutics Inc. From 04/25/24

2024-04-25 14:16:08 ET More on VistaGen Therapeutics Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiet...

Vistagen Therapeutics (NASDAQ: VTGN ), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, is reporting positive results from a phase 2A pilot study of PH15, its investigati...

PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A pilot study in sleep-deprived participants PH15 was safe and well-tolerated with an adverse event profile similar to placebo Vistagen (Nasdaq: VTGN),...

2024-04-24 10:33:24 ET Summary Vistagen Therapeutics, Inc. is developing a pipeline of drugs centered around pherines, odorless, neuroactive steroids that act through sensory neurons in the nose. The company has seen impressive results from a phase 3 study of PH94B in patients wit...

2024-04-19 07:13:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re searching for stocks under $15, look no further. These seven offerings, all priced below $15, present a unique opportunity for individual investors to profit from future develo...

2024-04-09 13:28:44 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Finding possibilities in investing frequently depends on finding companies attached to rapid expansion and value generation. Examine these three prospects, each selling at less than $10 per sha...

Vistagen Therapeutics (NASDAQ: VTGN ), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, will present posters at this week’s Anxiety and Depression Association of A...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an ...

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. The company today announced that it has enrolled the first patient in its PALISADE-3 Phase 3 ...

Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorder Social anxiety disorder affects over 25 million Americans Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to delive...